Aortic stenosis (AS) is the most common valve disease. Aortic-valve replacement (AVR) is the treatment of choice in symptomatic patients with severe AS. Our objective was to assess the prognostic value of NT-proBNP in Algerian patients with asymptomatic moderate/severe aortic.

Prospective study of 225patients with degenerative asymptomatic moderate/severe aortic stenosis. NT-proBNP was determined in all patients, who were then followed up clinically. A clinical event was defined as surgery, hospital admission due to angina, heart failure or syncope, or death.

A total of 51% were women, and the mean age was 74years. Mean (SD) echocardiographic values were as follows: peak velocity 4.14 (0.87) m/s; mean gradient, 43.2 (16.0) mmHg; aortic-valve area, 0.87 (0.72) cm², and aortic-valve area index, 0.49 (0.14) cm²/m². The median NT-pro-BNP value was 490.0 [198.0–1312.0] pg/mL. There were 139 events during follow-up (median 12months). The optimum NT-proBNP cut-point was 515pg/mL, giving event-free survival rates at 6months and 1years of 93% and 57%, respectively, in patients with NT-proBNP <515pg/mL compared with 50% and 31% in those with NT-proBNP >515pg/mL.

NT-proBNP determination provides prognostic information in patients with asymptomatic moderate/severe aortic stenosis.